UPDATE 1-Amgen antibody shows promise in myeloma trial, gets FDA fast track
December 04, 2018 at 00:20 AM EST
Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.
